Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00852995 · ClinicalTrials.gov registry record · Phase 2
Dose Finding Study of HP802-247 in Venous Leg Ulcers
A Phase 2 study, sponsored by Healthpoint.
- Completed
- Registry status
- Phase 2
- Development phase
- 228
- Enrollment target
NCT00852995 is a Phase 2 study that has completed, run by Healthpoint. The registered enrollment target is 228 participants.
The verdict
NCT00852995, a Phase 2 study, has completed, sponsored by Healthpoint.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 228 participants
- Enrollment target
Study Summary
This is a 16-week study for subjects with a venous leg ulcer between the knee and ankle. This research is being done to determine the effectiveness of two dosing frequencies and two different concentrations of HP802-247, together with standard care, compared to placebo, plus standard care.
Interventions
- BIOLOGICAL HP802-247
- BIOLOGICAL Placebo (Vehicle)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2009-02 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00852995
The ClinicalTrials.gov registry entry for NCT00852995 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 228 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Healthpoint, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which HP802-247 is the first listed.
NCT00852995 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00852995 about?
NCT00852995 is a clinical study titled "Dose Finding Study of HP802-247 in Venous Leg Ulcers". This is a 16-week study for subjects with a venous leg ulcer between the knee and ankle. This research is being done to determine the effectiveness of two dosing frequencies and two different concentrations of HP802-247, together with standard care, compared to placebo, plus standard care.
What is the current status of trial NCT00852995?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 228 participants. The study started on 2009-02. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00852995?
The interventions under investigation include: HP802-247 (BIOLOGICAL), Placebo (Vehicle) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00852995?
This trial is sponsored by Healthpoint, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.